Scalable, semi-automated fluorescence reduction neutralization assay for qualitative assessment of Ebola virus-neutralizing antibodies in human clinical samples.
Animals
Antibodies, Blocking
/ immunology
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
Chlorocebus aethiops
Disease Outbreaks
Ebolavirus
/ immunology
Enzyme-Linked Immunosorbent Assay
Hemorrhagic Fever, Ebola
/ immunology
Humans
Liberia
Neutralization Tests
/ methods
Vero Cells
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
19
04
2019
accepted:
06
08
2019
entrez:
28
8
2019
pubmed:
28
8
2019
medline:
7
3
2020
Statut:
epublish
Résumé
Antibody titers against a viral pathogen are typically measured using an antigen binding assay, such as an enzyme-linked immunosorbent assay (ELISA), which only measures the ability of antibodies to identify a viral antigen of interest. Neutralization assays measure the presence of virus-neutralizing antibodies in a sample. Traditional neutralization assays, such as the plaque reduction neutralization test (PRNT), are often difficult to use on a large scale due to being both labor and resource intensive. Here we describe an Ebola virus fluorescence reduction neutralization assay (FRNA), which tests for neutralizing antibodies, that requires only a small volume of sample in a 96-well format and is easy to automate. The readout of the FRNA is the percentage of Ebola virus-infected cells measured with an optical reader or overall chemiluminescence that can be generated by multiple reading platforms. Using blinded human clinical samples (EVD survivors or contacts) obtained in Liberia during the 2013-2016 Ebola virus disease outbreak, we demonstrate there was a high degree of agreement between the FRNA-measured antibody titers and the Filovirus Animal Non-clinical Group (FANG) ELISA titers with the FRNA providing information on the neutralizing capabilities of the antibodies.
Identifiants
pubmed: 31454374
doi: 10.1371/journal.pone.0221407
pii: PONE-D-19-11230
pmc: PMC6711594
doi:
Substances chimiques
Antibodies, Blocking
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Banques de données
ClinicalTrials.gov
['NCT02431923']
Dryad
['10.5061/dryad.4mv6600']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0221407Subventions
Organisme : NIAID NIH HHS
ID : HHSN272200700016I
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Viruses. 2012 Oct 19;4(10):2312-6
pubmed: 23202465
Arch Virol. 2014 Apr;159(4):821-30
pubmed: 24122154
N Engl J Med. 2014 Oct 9;371(15):1418-25
pubmed: 24738640
Viruses. 2016 Apr 21;8(4):113
pubmed: 27110807
N Engl J Med. 2017 Oct 12;377(15):1438-1447
pubmed: 29020589
J Infect Dis. 2018 Jan 4;217(2):223-231
pubmed: 29253164
J Virol Methods. 2018 Apr;254:1-7
pubmed: 29355585
J Virol Methods. 2018 May;255:84-90
pubmed: 29481881
PLoS One. 2018 Mar 22;13(3):e0194880
pubmed: 29566079
Lancet. 2018 Jul 21;392(10143):213-221
pubmed: 30047375
BMJ. 2018 Aug 7;362:k3421
pubmed: 30087112
J Infect Dis. 2018 Nov 5;218(12):1929-1936
pubmed: 30107445
Trends Microbiol. 2019 Jan;27(1):8-16
pubmed: 30201511